Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 6/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
| ▸ | GNPAT | O15228 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.33 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7576584 | 0.85 | ANPEP (0.44) | FOLH1GSRRNPEPCPB2SIRT6 | |
| SCHEMBL6151760 | 0.85 | FOLH1 (0.41) | FOLH1GSRRNPEPCPB2SIRT6 | |
| SCHEMBL27507131 | 0.81 | FOLH1 (0.46) | FOLH1GSRRNPEPCPB2SIRT6 | |
| SCHEMBL21412801 | 0.80 | SIRT6 (0.52) | FOLH1GSRCPB2SIRT6SIRT1 | |
| SCHEMBL14178208 | 0.80 | SIRT6 (0.52) | FOLH1GSRCPB2SIRT6SIRT1 | |
| SCHEMBL27789636 | 0.80 | GSR (0.40) | FOLH1GSRRNPEPCPB2SIRT6 | |
| SCHEMBL10907791 | 0.78 | ANPEP (0.39) | FOLH1CPB2SIRT6SIRT1GNPAT | |
| SCHEMBL12938437 | 0.78 | FOLH1 (0.44) | FOLH1GSRRNPEPCPB2SIRT6 | |
| SCHEMBL1272606 | 0.78 | FOLH1 (0.58) | FOLH1GSRRNPEPCPB2GNPAT | |
| SCHEMBL1272601 | 0.78 | FOLH1 (0.58) | FOLH1GSRRNPEPCPB2GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111989339-A | Hydrophobic auristatin F compounds and conjugates thereof | 西雅图基因公司 | 2020-11-24 | — | — | CN | claimed |
| US-11857700-B2 | Device with microstructure mediated absorption profile | BVW HOLDING AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-11844875-B2 | Microstructured haptotaxic implant | BVW HOLDING AG (CH) | 2023-12-19 | — | — | US | disclosed |
| CN-109952118-B | Microstructured chemotactic implant | BVW控股公司 | 2022-08-30 | — | — | CN | disclosed |
| US-20220211905-A1 | MICROSTRUCTURED HAPTOTAXIC IMPLANT | BVW HOLDING AG (CH) | 2022-07-07 | — | — | US | disclosed |
| US-11331408-B2 | Class of anti-adhesion hydrogels with healing aspects | BVW HOLDING AG (CH) | 2022-05-17 | — | — | US | disclosed |
| CN-109891021-B | Sizing agent for carbon fiber, aqueous dispersion of sizing agent for carbon fiber, and carbon fiber bundle having sizing agent attached thereto | 三菱化学株式会社 | 2022-04-12 | — | — | CN | disclosed |
| US-20220031734-A1 | Medical Device Comprising Boswellic Acid | BVW HOLDING AG (CH) | 2022-02-03 | — | — | US | disclosed |
| US-20210290820-A1 | MICROSTRUCTURED HAPTOTAXIC IMPLANT | BVW HOLDING AG (CH) | 2021-09-23 | — | — | US | disclosed |
| US-11123364-B2 | Medical device comprising boswellic acid | BVW HOLDING AG (CH) | 2021-09-21 | — | — | US | disclosed |
| CN-103889434-A | Medical device comprising boswellic acid | BVW HOLDING AG | 2014-06-25 | — | — | CN | disclosed |
| EP-2723357-A1 | MEDICAL DEVICE COMPRISING BOSWELLIC ACID | BVW Holding AG (CH) | 2014-04-30 | — | — | EP | disclosed |
| WO-2013112381-A2 | NEW CLASS OF ANTI-ADHESION HYDROGELS WITH HEALING ASPECTS | BVW HOLDING AG (CH) | 2013-08-01 | — | — | WO | disclosed |
| US-20130196003-A1 | CLASS OF ANTI-ADHESION HYDROGELS WITH HEALING ASPECTS | BVW HOLDING AG (CH) | 2013-08-01 | — | — | US | disclosed |
| WO-2012177825-A1 | MEDICAL DEVICE COMPRISING BOSWELLIC ACID | BVW HOLDING AG (CH) | 2012-12-27 | — | — | WO | disclosed |
| EP-2367624-A1 | USE OF A PISTON REACTOR TO IMPLEMENT A PHOSGENATION PROCESS | Perstorp France (FR) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010076515-A1 | USE OF A PISTON REACTOR TO IMPLEMENT A PHOSGENATION PROCESS | PERSTORP FRANCE (FR) | 2010-07-08 | — | — | WO | disclosed |
| US-20090324489-A1 | Wortmannin conjugates and uses thereof | BETH ISRAEL DEACONESS MEDICAL CENTER | 2009-12-31 | — | — | US | disclosed |
| EP-1940386-A2 | WORTMANNIN CONJUGATES AND USES THEREOF | Beth Israel Deaconess Medical Center (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007086943-A2 | WORTMANNIN CONJUGATES AND USES THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324489-A1 | Wortmannin conjugates and uses thereof | PIK3CG, PIK3C3, PIK3CA | FOLH1 3288/4885GSR 3739/4885RNPEP 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.